






































Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake
in Amyloidotic Cardiomyopathy
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Abstract: 99mTc-DPD (99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid)
has a high affinity for transthyretin (TTR)-infiltrated myocardium, allowing a dif-
ferential diagnosis with light chain cardiac amyloidosis and other nonamyloidotic
cardiomyopathies with a hypertrophic phenotype, in which myocardial tracer up-
take is low or absent. Myocardial bone tracer uptake in the rarer forms of amy-
loidosis (eg, apolipoprotein-related) has been rarely studied. We present 4 cases
of cardiac amyloidosis that underwent 99mTc-DPD scintigraphy; myocardial
DPD uptake was present in patients with ATTR, wtTTR and apolipoprotein AI
and negative in cases with AL and apolipoprotein AII-related disease.
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FIGURE 1. The role of 99mTc-DPD (99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid) scintigraphy in the diagnosis of
transthyretin (TTR)-related amyloidotic cardiomyopathy has been well documented in recent years.1,2 The affinity of DPD for
TTR-infiltratedmyocardiumhas proven useful in differentiating TTR-related amyloidosis from the primary light chain (AL) form and from
other nonamyloidotic cardiomyopathies with a hypertrophic phenotype.3,4 Knowledge regarding myocardial bone tracer uptake in
the rarer forms of amyloidosis (eg, apolipoprotein related5–7) is limited.8 In 2 cases of biopsy-proven cardiac amyloidosis that recently
underwent 99mTc-DPD scintigraphy at our center, myocardial uptake was present in apolipoprotein AI (ApoAI)8 and negative in
apolipoprotein AII (ApoAII). These findings therefore configure an extreme heterogeneity of myocardial uptake in amyloidosis that
seems to depend on etiology rather than on ventricular wall thickness (expression of the degree of infiltration). Our image shows late
DPD sequences (180 minutes after DPD administration, previously described methods1) in 5 different cases of biopsy-proven
amyloidotic cardiomyopathy; myocardial tracer uptake is intense in the mutated TTR-related form (ATTR), in wild-type TTR-related
(wtTTR), and in ApoAI; on the contrary, no uptake can be appreciated in AL or ApoAII despite similar wall thickness (maximum, 18mm).
Our images therefore strengthen the concept that DPD uptake is mainly determined by the specific etiology of amyloidosis and not by
the severity of myocardial amyloidotic infiltration.
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